title: First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs.
abstract: Ifoxetine (CGP 15 210 G) is a novel and unusual drug. It specifically and selectively blocks the 5-HT reuptake in the brain without affecting the 5-HT uptake processes in the periphery (blood platelets). In the first, open and explorative trials its tolerability and effectiveness were studied in 33 patients suffering from endogenous (n = 25) or other types of depressive disorders. In daily doses of 50 to maximally 300 mg mental condition considerably improved in 17 patients. As assessed by HAMD 7 patients out of 17 became asymptomatic (HAMD Score less than 10) whereas 10 other patients markedly improved (decrease in HAMD by greater than or equal to 50%) in the course of 3 to 4 weeks of treatment. Eleven patients improved only slightly, in 3 patients no particular change in condition could be observed and 2 patients deteriorated. This deterioration was due to psychotic decompensation after the second week of the treatment (75-100 mg/d). Apart from this, ifoxetine was well tolerated particularly at doses of 50-150 mg/day, which also appeared to be the optimal therapeutic range of doses. There were no changes in cardiovascular function or laboratory values and almost no somatic or other complaints of major concern. These preliminary results indicate that ifoxetine has antidepressant properties with possibly an advantageous side-effect profile, in comparison to other 5-HT uptake inhibitors.
authors.affiliation: CIBA-GEIGY Frankfurt.
authors.forename: A
authors.initials: A
authors.lastname: Delini-Stula
authors.forename: R
authors.initials: R
authors.lastname: Fischbach
authors.forename: J M
authors.initials: JM
authors.lastname: Gauthier
authors.forename: H
authors.initials: H
authors.lastname: Richou
authors.forename: G
authors.initials: G
authors.lastname: Rothweiler
authors.forename: G
authors.initials: G
authors.lastname: Wendt
authors.forename: M
authors.initials: M
authors.lastname: Wolfersdorf
mesh_terms: D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000009:adverse effects
chemical_list: D010880:Piperidines; D012702:Serotonin Antagonists; C046382:ifoxetine